Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective as of market open on Monday, Dec. 20.
“We are proud to announce our addition to the esteemed Nasdaq Biotechnology Index,” George Goldsmith, CEO and founder of Compass Pathways said. “Our inclusion in this index enables us to reach new audiences as we continue to execute on our clinical development of our investigational COMP360 psilocybin therapy in hopes of addressing the most challenging issues in mental healthcare.”
The NBI is designed to track the performance of a set of securities listed on the
